ADVANCED MELANOMA
Clinical trials for ADVANCED MELANOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED MELANOMA trials appear
Sign up with your email to follow new studies for ADVANCED MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat melanoma
Disease control CompletedThis early-phase study tested a new drug called LBL-007 combined with toripalimab (and sometimes axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety, find the best dose, and see if tumors shrink. Pa…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New combo shot shows promise for Tough-to-Treat melanoma
Disease control CompletedThis study tested a drug called LTX-315, injected directly into accessible tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 23 people with advanced melanoma that had stopped responding to prior PD-1/PD-L1 inhibitors. The goal was to see if this combination coul…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy shows promise for Tough-to-Treat melanoma
Disease control CompletedThis early-phase study tested a combination of two drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to standard treatments. The main goals were to find the safest dose and see if the combination could shrink tumors. The study is com…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Experimental shot targets tumors in Late-Stage cancers
Disease control CompletedThis early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab. It included 6 adults with advanced head and neck, melanoma, or triple-negative breast cancer that had spread. The goal was to see if the combinat…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Personalized vaccine shows promise against deadly skin cancer
Disease control CompletedThis study tested a new personalized cancer vaccine (RO7198457) combined with the immunotherapy drug pembrolizumab in 131 people with advanced melanoma that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone at slowing cance…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Blood tests may reveal who will beat melanoma
Knowledge-focused CompletedThis study examined blood and tumor samples from 25 people with advanced melanoma to understand why some respond to the immunotherapy drug pembrolizumab while others do not. Researchers focused on T cells, a type of immune cell, to find genetic clues that could predict treatment …
Matched conditions: ADVANCED MELANOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 17, 2026 06:48 UTC
-
Cancer moonshot study banks tissue to unlock genetic secrets
Knowledge-focused CompletedThis study collected blood and tumor tissue from 64 people with advanced or treatment-resistant cancers. Researchers stored these samples to study how genes affect cancer growth and response to therapy. The goal is to better understand why some cancers stop responding to treatmen…
Matched conditions: ADVANCED MELANOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 06:46 UTC